PSYCHEDELICS IN PSYCHIATRY AND BEYOND
BRAXIA SCIENTIFIC TO PRESENT AT THE PSYCHEDELICS IN PSYCHIATRY AND BEYOND VIRTUAL CONFERENCE HOSTED BY H.C. WAINWRIGHT & CO. ON JUNE 17, 2021 TORONTO, ONTARIO June 9, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Psychedelics in Psychiatry and Beyond Virtual Conference, hosted by H.C. Wainwright & Co. on June 17, 2021. Braxia’s CEO, Dr. Roger McIntyre will present and participate in a panel discussion, “Patient Experience And Commercial Considerations When Launching Psychoactive Agents In Psychiatry.” Dr. McIntyre will also be available to host virtual one-on-one meetings with institutional investors registered with H.C. Wainwright and Co. For additional information on the conference please visit: https://hcwevents.com/psychedelics/ About Braxia Scientific Corp. Braxia Scientific is a...
KETAMINE AND ESKETAMINE TREATMENT GUIDANCE
AMERICAN JOURNAL OF PSYCHIATRY PUBLISHES INTERNATIONAL KETAMINE AND ESKETAMINE TREATMENT GUIDANCE LED BY BRAXIA SCIENTIFIC CEO DR. ROGER MCINTYRE International Expert Opinion and Implementation Guidance outlines Ketamine and Esketamine treatment parameters setting the standard for the clinical implementation of these rapid-acting treatments in treatment resistant depression Guidance published in the official Journal of the American Psychiatric Association establishes Braxia Scientific as an international leader in the rapidly evolving industry of Ketamine, Esketamine and rapid acting antidepressants TORONTO, ONTARIO June 9, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce the American Journal of Psychiatry, the most widely read psychiatric journal in the world, has published the International Expert Opinion and Implementation Guidance (the “Guidelines”) for the clinical use of...
DR. DAVID GREENBERG TO BOARD OF DIRECTORS
BRAXIA SCIENTIFIC APPOINTS DR. DAVID GREENBERG TO BOARD OF DIRECTORS TORONTO, ONTARIO May 31, 2021 – Braxia Scientific Corp. (the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a research driven clinical platform developing and providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce it has appointed Dr. David Greenberg to its Board of Directors. A nationally recognized general medical practitioner for more than 30 years and a lecturer at The University of Toronto in the Department of Family and Community Medicine, Dr. David Greenberg brings extensive experience in Mental Health and Concussions. He has developed and implemented multiple education programs for medical practitioners, nationally and internationally, and is regarded as an international health expert and keynote speaker on the topic of depression and related disorders. Dr. Greenberg is the Team Physician for the Toronto Argonauts,...
THE BRAXIA INSTITUTE
BRAXIA SCIENTIFIC INTRODUCES THE BRAXIA INSTITUTE Over 200 physicians and healthcare providers from Canada, U.S., and Asia to attend Braxia’s Symposium on rapid acting anti-depressants (RAAD) which include ketamine, esketamine and psychedelic therapies Braxia Institute aims to turn research into clinical action to achieve better outcomes for people with mental illness by closing the extraordinary gap between clinical practice and neuroscience research of ketamine and psychedelic treatment TORONTO, ONTARIO May 20, 2021 – Braxia Scientific Corp. (“Braxia Scientific” or the “Company”), (CSE: BRAX) (FWB: 496) (OTC: SHRMF), a research driven clinical platform developing and providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce the launch of the Braxia Institute (“Braxia Institute”), the Company’s training Centre of Excellence focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment therapy for people with...
SYMBOL CHANGE ON OTC MARKETS TO “BRAXF"
BRAXIA SCIENTIFIC ANNOUNCES SYMBOL CHANGE ON OTC MARKETS TO “BRAXF” In Quebec, ~20% of the population, or 1 in 5 people, experience mental illness during their lifetime; Covid-19 has further exacerbated the number of adults experiencing symptoms of major depression This joint venture creates first privately owned clinic in Quebec to address unmet need for accessible, high-quality, advanced mental health services and treatments for depression, suicide, and other mental health disorders including providing access to rapid-onset treatments such as Intravenous ketamine Established in 2006, Neurotherapy Montreal provides access to large network of physicians across Quebec, including +1,200 psychiatrists Neurotherapy Montreal’s large, established patient base includes patients diagnosed with brain-based injuries such as Anxiety, Depression, Attention Deficit Hyperactivity Disorder (ADHD), Traumatic Brain Injury, Stroke, Multiple Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, Chronic Pain, Vestibular and Sleep Disorder The Braxia clinic is situated...
FIRST KETAMINE THERAPY CLINIC IN QUEBEC
In Quebec, ~20% of the population, or 1 in 5 people, experience mental illness during their lifetime; Covid-19 has further exacerbated the number of adults experiencing symptoms of major depression This joint venture creates first privately owned clinic in Quebec to address unmet need for accessible, high-quality, advanced mental health services and treatments for depression, suicide, and other mental health disorders including providing access to rapid-onset treatments such as Intravenous ketamine Established in 2006, Neurotherapy Montreal provides access to large network of physicians across Quebec, including +1,200 psychiatrists Neurotherapy Montreal’s large, established patient base includes patients diagnosed with brain-based injuries such as Anxiety, Depression, Attention Deficit Hyperactivity Disorder (ADHD), Traumatic Brain Injury, Stroke, Multiple Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, Chronic Pain, Vestibular and Sleep Disorder The Braxia clinic is situated within a 14,000 square foot multi-disciplinary state of the art...
BRAXIA SCIENTIFIC INTRODUCES “BRAXIA HEALTH”
BRAXIA SCIENTIFIC INTRODUCES “BRAXIA HEALTH” A GROWING NETWORK OF CLINICS LEADING NOVEL PSYCHEDELIC RESEARCH AND TREATMENTS FOR MENTAL DISORDERS Braxia Scientific enters a new chapter as it commences trading under its new ticker “CSE: BRAX” and rebrands its growing network of leading clinics to Braxia Health, which includes the Canadian Rapid Treatment Centre of Excellence established in 2018. Only clinic in Canada previously involved in a randomized controlled pivotal trial for regulatory approval purposes of psilocybin for the treatment of adults with depression. Led by Dr. Roger McIntyre, the top-rated expert in depression since 2010 as rated by Expertscape, Braxia Health has the largest clinical research footprint for ketamine and psychedelic-based research in the world, providing the fastest route to development of its IP capable formulations and IP capable delivery methods. First community-based centre in Canada to specialize in rapid-acting treatments...
COMMENTS ON PROSPECTIVE CLASS PROCEEDING
BRAXIA SCIENTIFIC CORP. COMMENTS ON PROSPECTIVE CLASS PROCEEDING TORONTO, ONTARIO May 3, 2021 – Braxia Scientific Corp. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), (formerly Champignon Brands Inc.) announces that it was served with a notice of civil claim in a proposed class proceeding in British Columbia against the Company, its CEO, certain of its former officers, a shareholder, and underwriters which were engaged in connection with a private placement financing for the Company in June 2020. The Company has accepted service as of today’s date. The claim is based on allegations relating to the Company’s disclosure documents regarding the value of four acquisitions made by the Company in 2020 and related matters. The plaintiff is seeking an unspecified amount of damages for the proposed class. The Company intends to vigorously defend the claim. About Braxia Scientific Corp. Braxia...
CHANGES NAME TO BRAXIA SCIENTIFIC CORP
CHAMPIGNON BRANDS CHANGES NAME TO BRAXIA SCIENTIFIC TO REFLECT THE INTEGRATION OF KETAMINE AND PSYCHEDELIC CLINICS AND ITS RESEARCH AND DEVELOPMENT PRIORITIES TORONTO, ONTARIO May 3, 2021 – Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), is pleased to announce that it has changed its name from “Champignon Brands Inc.” to “Braxia Scientific Corp.” and its ticker symbol will change from “SHRM” to “BRAX” on the Canadian Securities Exchange (the “CSE”). The name change reflects the Company’s commitment to providing access to, and leadership in, setting the standard of care for ketamine treatment in depression through its network of clinics, as well as the Company’s ketamine and psychedelic derivative research and drug development priorities. Braxia Scientific’s overarching aim is to shape the future of treatment for people suffering from depression and other mental health disorders. “Our new...
REVOCATION OF CEASE TRADE ORDERS
TORONTO, ONTARIO April 22, 2021 - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), is pleased to announce that the British Columbia Securities Commission and Ontario Securities Commission (the “Commissions”) have revoked their cease trade orders against the Company effective April 22, 2021.
CHAMPIGNON BRANDS ANNOUNCES FILING OF LISTING STATEMENT
TORONTO, ONTARIO, March 26, 2021 /CNW Telbec/ - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announced today that it has filed a new Listing Statement with the Canadian Securities Exchange ("CSE") which contains disclosure regarding the acquisition of AltMed Capital Corp. (“AltMed”) (the “Transaction”). The Transaction constituted a reverse takeover of Champignon by AltMed.
RESTATES FINANCIAL STATEMENTS AND MD&A LISTING
VANCOUVER, BRITISH COLUMBIA – March 11, 2021 - Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announced that as a result of a review by the British Columbia Securities Commission (the “Commission”), the Company has refiled its condensed interim consolidated financial statements and management’s discussion & analysis (“MD&A”) for the three and six month periods ended March 31, 2020 (the “Restated Financial Statements and MD&A”).